Technical Analysis for RVX - Resverlogix Corp.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.060 | 9.09% | 0.005 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Fell Below 20 DMA | Bearish | 9.09% | |
| Fell Below 50 DMA | Bearish | 9.09% |
| Alert | Time |
|---|---|
| Gapped Up (Full) | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Rose Above 50 DMA | 1 day ago |
| Rose Above 20 DMA | 1 day ago |
| Rose Above 10 DMA | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: 2018-12-18
Resverlogix Corp. Description
Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Beta Clinic Biotechnology Disease RTT Medical Specialties Diseases Clinical Trial IPO Diabetes Alzheimer's Disease Chronic Condition Chronic Kidney Diabetes Mellitus Kidney Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.17 |
| 52 Week Low | 0.05 |
| Average Volume | 29,618 |
| 200-Day Moving Average | 0.073 |
| 50-Day Moving Average | 0.059 |
| 20-Day Moving Average | 0.056 |
| 10-Day Moving Average | 0.057 |
| Average True Range | 0.004 |
| RSI (14) | 56.14 |
| ADX | 13.24 |
| +DI | 33.594 |
| -DI | 22.656 |
| Chandelier Exit (Long, 3 ATRs) | 0.049 |
| Chandelier Exit (Short, 3 ATRs) | 0.061 |
| Upper Bollinger Bands | 0.061 |
| Lower Bollinger Band | 0.052 |
| Percent B (%b) | 0.93 |
| BandWidth | 15.275 |
| MACD Line | 0.000 |
| MACD Signal Line | -0.001 |
| MACD Histogram | 0.0008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.060 | ||||
| Resistance 3 (R3) | 0.060 | 0.060 | 0.060 | ||
| Resistance 2 (R2) | 0.060 | 0.060 | 0.060 | 0.060 | |
| Resistance 1 (R1) | 0.060 | 0.060 | 0.060 | 0.060 | 0.060 |
| Pivot Point | 0.060 | 0.060 | 0.060 | 0.060 | 0.060 |
| Support 1 (S1) | 0.060 | 0.060 | 0.060 | 0.060 | 0.060 |
| Support 2 (S2) | 0.060 | 0.060 | 0.060 | 0.060 | |
| Support 3 (S3) | 0.060 | 0.060 | 0.060 | ||
| Support 4 (S4) | 0.060 |
